HuidaGene Therapeutics

About:

HuidaGene is a global clinical-stage biotechnology company pioneering innovative gene therapies for neurology and ophthalmology.

Website: http://www.huidagene.com/

Top Investors: Hillhouse Investment, WuXi AppTec, CD Capital, Sherpa Healthcare Partners, Huimei Capital

Description:

HuidaGene utilizes its proprietary CRISPR-based, AI-driven HG-PRECISE platform to develop potentially curative gene therapies. The Company is advancing clinical programs, including trials of HG004 (granted ODD & RPDD by FDA) for RPE65-associated retinal disease, HG202 RNA-editing therapy for nAMD, HG204 RNA-editing therapy (granted ODD & RPDD by FDA and ODD by EMA) for MECP2 duplication syndrome, and HG302 DNA-editing therapy (granted ODD & RPDD by FDA) for DMD. The preclinical programs include HG303 DNA-editing for ALS and CRISPR RNA-editing therapy for Alzheimer’s.